5 assets in Squamous Cell Carcinoma Of Pancreas

Therapeutic assets addressing Squamous Cell Carcinoma Of Pancreas, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Squamous Cell Carcinoma Of Pancreas	Alliance for Clinical Trials in Oncology	P2/3	B (57)
Olaparib Squamous Cell Carcinoma Of Pancreas	National Cancer Institute (NCI)	P2	CCC (53)
Domvanalimab Squamous Cell Carcinoma Of Pancreas	James Cleary, MD, PhD	P1/2	CCC (48)
Zimberelimab Squamous Cell Carcinoma Of Pancreas	James Cleary, MD, PhD	P1/2	CCC (48)
Sotigalimab Squamous Cell Carcinoma Of Pancreas	James Cleary, MD, PhD	P1/2	CC (45)